NasdaqGM - Nasdaq Real Time Price USD

RxSight, Inc. (RXST)

Compare

14.08

-0.11

(-0.78%)

At close: 4:00:00 PM EDT

13.91

-0.17

(-1.22%)

After hours: 6:12:18 PM EDT

JP Morgan downgrades RxSight on market, competitive pressures

Investing.com -- JP Morgan downgraded RxSight to Underweight, citing market, economic, and competitive headwinds that have led to a weaker-than-expected first-quarter performance and a downward revision to 2025 guidance. The firm set a $17 price target on the stock.

Investing.com 7 days ago

RXST
-0.78%
Block upgraded, Nvidia downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Morgan Stanley upgraded Block (XYZ) to Overweight from Equal Weight with a price target of $67, up from $65. The firm sees a “compelling” valuation at current share levels and low expectations for reaccelerated Square Seller growth. Cantor Fitzgerald upgraded Zscaler (ZS) to Overweight from Neutral wit

TipRanks 7 days ago

NVDA

ESI

FAST
Is RxSight, Inc. (NASDAQ:RXST) Trading At A 39% Discount?

Key Insights The projected fair value for RxSight is US$26.71 based on 2 Stage Free Cash Flow to Equity Current share...

Simply Wall St. 7 days ago

RXST
-0.78%
RxSight Inc (RXST) Q1 2025 Earnings Call Highlights: Strong Year-Over-Year Growth Amid Revised ...

Despite a 28% revenue increase, RxSight Inc (RXST) adjusts its full-year outlook due to macroeconomic challenges and market conditions.

GuruFocus.com 7 days ago

RXST
-0.78%
Preliminary Q1 2025 Rxsight Inc Earnings Call

Preliminary Q1 2025 Rxsight Inc Earnings Call

Thomson Reuters StreetEvents 7 days ago

RXST
-0.78%
RxSight Plunges 44% After Slashing 2025 Guidance; Bank of America Downgrades Stock

Q1 2025 revenue expected at $37.9 million, below the $39.6 million FactSet estimate.

GuruFocus.com 8 days ago

RXST
-0.78%
RxSight Q1 Revenue Miss, Guidance Cut Raise Growth Concerns, BofA Says

RxSight's (RXST) Q1 revenue shortfall and lower 2025 guidance raise concerns about slowing growth an

PREMIUM
MT Newswires 8 days ago

RXST
-0.78%
RxSight Warns On FY25 Revenue As Premium Cataract Market Faces Headwinds, Stock Plunges

RxSight, Inc. (NASDAQ:RXST) shares are trading lower premarket on Thursday. On Wednesday, the company disclosed first-quarter preliminary results and revised its FY25 outlook. The company sees first-quarter revenue of around $37.9 million, up 28% year over year and down 6% quarter over quarter, and below the consensus of $40.14 million. RxSight projects the sale of 27,579 Light Adjustable Lenses (LAL/LAL+), with a growth of 36%Y/Y increase in procedure volume. Also, the company anticipates the s

Benzinga 8 days ago

RXST
-0.78%
RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance

ALISO VIEJO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary revenue results for the first quarter 2025 and revised full-year 2025 guidance. The Company will host a conference call on Thursday, April 3, 2025, at 8:00 a.m. Eastern Time. Preliminary First Quarter 2025 Results Preliminary first quarter 2025 r

GlobeNewswire 8 days ago

RXST
-0.78%
RxSight, Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference

ALISO VIEJO, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming 24th Annual Needham Virtual Healthcare Conference. RxSight’s management is scheduled to participate in a fireside chat on Tuesday, April 8, 2025, at 9:45 a.m. Pacific Time / 12:45 p.m. Eastern Time. A live and archived webcast

GlobeNewswire 17 days ago

RXST
-0.78%
RxSight, Inc. (NASDAQ:RXST) Just Reported, And Analysts Assigned A US$44.80 Price Target

Last week, you might have seen that RxSight, Inc. ( NASDAQ:RXST ) released its annual result to the market. The early...

Simply Wall St. last month

RXST
-0.78%
RxSight Full Year 2024 Earnings: EPS Beats Expectations

RxSight ( NASDAQ:RXST ) Full Year 2024 Results Key Financial Results Revenue: US$139.9m (up 57% from FY 2023). Net...

Simply Wall St. last month

RXST
-0.78%
RxSight Inc (RXST) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...

RxSight Inc (RXST) reports a 41% revenue increase and unveils new FDA-approved functionalities, setting the stage for continued growth in 2025.

GuruFocus.com last month

RXST
-0.78%
RxSight, Inc. (RXST) Misses Q4 Earnings Estimates

RxSight (RXST) delivered earnings and revenue surprises of -70% and 0.07%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

RXST
-0.78%
RxSight, Inc. Reports Fourth Quarter and Full-Year 2024 Financial Results, Reaffirms 2025 Guidance

ALISO VIEJO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced financial results for the three months and full-year ended December 31, 2024. Key Quarterly and Full-Year Highlights Recognized fourth quarter 2024 revenue of $40.2 million, an increase of 41% compared to the fourth quarter of 2023, reflecting: The sale of 29,069 Light Adjustable Le

GlobeNewswire last month

RXST
-0.78%
RxSight, Inc. to Report Fourth Quarter Financial Results on February 25, 2025

ALISO VIEJO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the fourth quarter of 2024 after the market close on Tuesday, February 25, 2025. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the c

GlobeNewswire last month

RXST
-0.78%
Insider Stock Buying Reaches US$1.83m On RxSight

Multiple insiders secured a larger position in RxSight, Inc. ( NASDAQ:RXST ) shares over the last 12 months. This is...

Simply Wall St. 2 months ago

RXST
-0.78%
RxSight price target lowered to $43 from $66 at Needham

Needham lowered the firm’s price target on RxSight (RXST) to $43 from $66 and keeps a Buy rating on the shares as part of a broader research note on MedTech/Diagnostics sector. Following the recent pre-announcements and management commentary, the firm is updating its forecasts on select names while also rolling forward its valuation framework to 2026 estimates, the analyst tells investors in a research note. Published first on TheFly – the ultimate source for real-time, market-moving breaking fi

TipRanks 2 months ago

RXST
-0.78%
RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and Operational Results and 2025 Guidance

ALISO VIEJO, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2024 and provided full-year 2025 guidance. Preliminary Unaudited Fourth Quarter and Full-year 2024 Results Preliminary unaudited fourth quarter 2024 revenue is expec

GlobeNewswire 2 months ago

RXST
-0.78%
RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference

ALISO VIEJO, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming J.P. Morgan Healthcare Conference. RxSight’s management is scheduled to present on Wednesday, January 15, 2025, at 9:45 a.m. Pacific Time / 12:45 p.m. Eastern Time. Interested parties may access a live and archived webcast of the

GlobeNewswire 3 months ago

RXST
-0.78%

Performance Overview

Return	RXST	S&P 500 (^GSPC)
YTD	-59.05%	-8.81%
1-Year	-74.54%	+3.16%
3-Year	+13.73%	+21.55%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

RxSight, Inc. (RXST)

JP Morgan downgrades RxSight on market, competitive pressures

Block upgraded, Nvidia downgraded: Wall Street’s top analyst calls

Is RxSight, Inc. (NASDAQ:RXST) Trading At A 39% Discount?

RxSight Inc (RXST) Q1 2025 Earnings Call Highlights: Strong Year-Over-Year Growth Amid Revised ...

Preliminary Q1 2025 Rxsight Inc Earnings Call

RxSight Plunges 44% After Slashing 2025 Guidance; Bank of America Downgrades Stock

RxSight Q1 Revenue Miss, Guidance Cut Raise Growth Concerns, BofA Says

RxSight Warns On FY25 Revenue As Premium Cataract Market Faces Headwinds, Stock Plunges

RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance

RxSight, Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference

RxSight, Inc. (NASDAQ:RXST) Just Reported, And Analysts Assigned A US$44.80 Price Target

RxSight Full Year 2024 Earnings: EPS Beats Expectations

RxSight Inc (RXST) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...

RxSight, Inc. (RXST) Misses Q4 Earnings Estimates

RxSight, Inc. Reports Fourth Quarter and Full-Year 2024 Financial Results, Reaffirms 2025 Guidance

RxSight, Inc. to Report Fourth Quarter Financial Results on February 25, 2025

Insider Stock Buying Reaches US$1.83m On RxSight

RxSight price target lowered to $43 from $66 at Needham

RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and Operational Results and 2025 Guidance

RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference

Performance Overview